Search Results - "Passos, V.Q."

CANOPY-1: A phase III, placebo-controlled study of pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) with/without canakinumab in untreated patients (pts) with stage IIIB/IIIC-IV NSCLC by Tan, D.S.W., Kim, T.M., Solomon, B.J., Tan, W.L., Yu, C.-J., Geater, S., De Castro, G., Greystoke, A., Felip, E., Johnson, B.E., Deudon, S., Louveau, A.-L., Passos, V.Q., Cho, B.C.

Get full text

Phase 2 study of ceritinib in ALKi-naïve patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): Whole body responses in the overall pt group and in pts with baseline brain metastases (BM) by Felip, E., Orlov, S., Park, K., Yu, C.-J., Tsai, C.-M., Nishio, M., Dols, M.C., McKeage, M., Su, W.-C., Mok, T.S.K., Scagliotti, G., Spigel, D.R., Passos, V.Q., Chen, V., Munarini, F., Shaw, A.

Get full text

Primary efficacy and updated safety of ceritinib (450 mg or 600 mg) with food vs 750 mg fasted in ALK+ metastatic NSCLC (ASCEND-8) by Cho, B.C., Obermannova, R., Orlov, S.V., Batra, U., Geater, S.L., McKeage, M., Yang, C.-T., Postmus, P.E., de Castro, G., Kim, S.-W., De Marchi, P., Kanakasetty, G.B., Sriuranpong, V., Voon, P.J., Lau, Y.Y., Kiertsman, F., Passos, V.Q., Chen, Z., Dziadziuszko, R.

Get full text

445PD ASCEND-6: single-arm, open label, multicenter phase 1/2 study of ceritinib in Chinese pts with advanced ALK- rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with crizotinib by Zhang, L., Shi, Y., Tan, D.S.W., Hu, B., Xiaoqing, L., Cheng, Y., Zhou, J., An, T., Lu, Y., Zhu, B., Bai, C., Jappe, A., Passos, V.Q., Lau, Y.Y., Wang, Q., Wu, Y.-L.

Get full text

445PD ASCEND-6: single-arm, open label, multicenter phase 1/2 study of ceritinib in Chinese pts with advanced ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with crizotinib by Zhang, L., Shi, Y., Tan, D.S.W., Hu, B., Xiaoqing, L., Cheng, Y., Zhou, J., An, T., Lu, Y., Zhu, B., Bai, C., Jappe, A., Passos, V.Q., Lau, Y.Y., Wang, Q., Wu, Y-L.

Get full text

Overall survival results of ceritinib in ALKi-naïve patients with ALK-rearranged NSCLC (ASCEND-3) by Felip, E., Nishio, M., Orlov, S., Park, K., Yu, C.-J., Tsai, C.-M., Cobo, M., McKeage, M., Su, W.-C., SK Mok, T., Scagliotti, G.V., Spigel, D., Passos, V.Q., Chen, Z., Shaw, A.T.

Get full text

Primary efficacy and updated safety of ceritinib (450mg or 600mg) with food vs 750mg fasted in ALK+ metastatic NSCLC (ASCEND-8) by Cho, B.C., Obermannova, R., Orlov, S.V., Batra, U., Geater, S.L., McKeage, M., Yang, C.-T., Postmus, P.E., de Castro, G., Kim, S.-W., De Marchi, P., Kanakasetty, G.B., Sriuranpong, V., Voon, P.J., Lau, Y.Y., Kiertsman, F., Passos, V.Q., Chen, Z., Dziadziuszko, R.

Get full text